AdAlta Ltd (ASX:1AD)'s CEO Dr Tim Oldham says they're continuing to build its pipeline using proprietary i-body technology to generate a promising new class of single-domain antibody-protein therapeutics to treat some of today’s most challenging medical conditions. The company's lead asset AD-214 is being prepared as an inhaled version for a phase II trial in Idiopathic Pulmonary Fibrosis (IPF), targeting a US$3 billion IPF market.
AdAlta well financed as it expands unique i-body technology pipeline
